Keyphrases
Carboplatin
100%
Paclitaxel
100%
Single Center
100%
Advanced Solid Tumors
100%
Multi-arm
100%
Phase Ib Study
100%
Selinexor
100%
Tumor Subtype
40%
Vomiting
40%
Nausea
40%
Partial Response
40%
Ovarian Cancer
20%
Breast Cancer
20%
Antitumor Activity
20%
Stable Disease
20%
Standard of Care
20%
Esophageal Cancer
20%
Chemotherapy Regimen
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Anemia
20%
Neutropenia
20%
Thrombocytopenia
20%
Breast
20%
Common Cancers
20%
In(III)
20%
Clinical Activity
20%
Conventional Chemotherapy
20%
Treatment-related Adverse Events
20%
Relapsed or Refractory
20%
Time to Treatment Failure
20%
Objective Response
20%
Leukopenia
20%
Refractory Solid Tumors
20%
Esophageal Adenocarcinoma
20%
First-in-class
20%
Exportin-1
20%
Trial Registration
20%
Disease Control Rate
20%
Clinical Progression
20%
Multiple Malignancies
20%
Nuclear Export Inhibitors
20%
Prior Exposure
20%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Carboplatin
100%
Paclitaxel
100%
Selinexor
100%
Diseases
40%
Neoplasm
40%
Antitumor Activity
20%
Chemotherapy
20%
Thrombocytopenia
20%
Neutropenia
20%
Breast Cancer
20%
Nausea
20%
Non Small Cell Lung Cancer
20%
Anemia
20%
Adverse Event
20%
Ovary Cancer
20%
Nausea and Vomiting
20%
Leukopenia
20%
Esophageal Adenocarcinoma
20%
Exportin 1
20%